Suven Life Sciences to Present Five Scientific Posters at AAIC 2026
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026, scheduled from July 12 to July 15 in London, covering updates on its global Phase-3 Masupirdine program for Alzheimer's-related agitation and the Usmarapride Phase-2 clinical development program. The company holds five clinical-stage CNS assets and plans to explore strategic partnering opportunities at the event.
*this image is generated using AI for illustrative purposes only.
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026, including updates on its global Phase-3 Masupirdine clinical program for agitation associated with Alzheimer's Dementia and the Usmarapride Phase-2 clinical development program. The conference is scheduled from July 12 to July 15, 2026, in London, United Kingdom. The presentations will provide insights into the study population and trial progress for Masupirdine, alongside broader non-clinical and clinical research advances across the company's neuroscience pipeline.
The AAIC serves as the largest international conference dedicated to advancing dementia science and clinical practice. Suven Life Sciences aims to engage with investigators, key opinion leaders, and the global research community during the event. The company also plans to explore strategic partnering opportunities for its clinical-stage central nervous system (CNS) portfolio with pharmaceutical and biotechnology companies.
Suven Presentations at AAIC 2026
The company's scientific team will present data across multiple sessions covering various CNS candidates:
| Presentation Title | Date | Time |
|---|---|---|
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a M1 PAM, in Healthy Human Subjects | July 12 | 7:30 AM - 4:15 PM |
| SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for the Treatment of Alzheimer's Disease and Schizophrenia | July 13 | 7:30 AM - 4:15 PM |
| Masupirdine (A Pure 5-HT6R Antagonist): Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Alzheimer's Dementia | July 15 | 7:30 AM - 4:15 PM |
| Usmarapride, selective 5-HT4R partial agonist: an update on the clinical development program for the treatment of cognitive disorders | July 15 | 7:30 AM - 4:15 PM |
| Efficacy and Safety of SUVN-N9503012, a Selective 5-HT1A Partial Agonist for the Symptomatic Treatment of Neurodegenerative Disorders | July 15 | 7:30 AM - 4:15 PM |
Clinical Pipeline Overview
Suven Life Sciences holds a portfolio of five clinical-stage assets focused on CNS disorders. Masupirdine (SUVN-502) is currently in a global Phase-3 study for the treatment of agitation in patients with dementia of the Alzheimer's type. Other assets include Samelisant (SUVN-G3031) for narcolepsy, Ropanicant (SUVN-911) for major depressive disorders, Usmarapride (SUVN-D4010) for cognitive disorders, and SUVN-I6107 for cognitive disorders. The company owns all intellectual property rights for its assets in all major markets.
Historical Stock Returns for Suven Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.05% | +10.18% | +30.39% | +127.75% | +21.55% | +284.96% |
What are the potential market impacts if Suven's Masupirdine successfully completes Phase-3 trials for agitation in Alzheimer's patients?
How might the strategic partnerships explored at AAIC 2026 influence Suven's future R&D and commercialization efforts?
What are the next milestones for Suven's other CNS candidates, such as Samelisant and Ropanicant, following the AAIC presentations?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
